Interventional Cardiologist - Golden Jubilee Hospital - NHS Scotland - BHF Glasgow Cardiovascular Research Centre - University of Glasgow - Views my own
Scotland, United Kingdom
Joined June 2018
- Tweets1.3K
- Following924
- Followers840
- Likes5.2K
Paul Rocchiccioli retweeted
Anomalous aortic origin of a #coronary artery (#AAOCA) can lead to ischemia and sudden cardiac death. Check out this #JACCIMG state-of-the-art review on standardized nomenclature describing anatomic and morphologic features of AAOCA. jacc.org/doi/10.1016/j.jcmg.… @chrisgraeni
Paul Rocchiccioli retweeted
Structural valve deterioration is an inherent limitation of bioprosthetic valves, and from the earliest days of transcatheter aortic valve replacement (TAVR), it was recognized that these devices would be no exception. The key question has never been whether deterioration occurs, but rather when it becomes clinically relevant and how the long-term durability of transcatheter valves compares with that of surgical bioprostheses. In our Editorial Comment for @JACCJournals, accompanying the 10-year results of the PARTNER 2A and PARTNER 2 S3i studies, we discuss the implications of these findings and their relevance to contemporary clinical practice. jacc.org/doi/10.1016/j.jacc.…
Paul Rocchiccioli retweeted
Unravelling the grey zone: submaximal-to-peak stress echocardiography enhances diagnostic accuracy in differentiating early dilated cardiomyopathy from physiological adaptation
link.springer.com/article/10…
#Excercisetest #Dilatedcardiomyopathy #Athletes #Sportscardiology
Paul Rocchiccioli retweeted
Scottish Rugby is immensely saddened to learn of the death earlier today of former Scotland and British & Irish Lions centre, Scott Hastings. He was 61.
Paul Rocchiccioli retweeted
We are currently recruiting for an Interventional Cardiologist to join our team at the Edinburgh Heart Centre.
This is a high-volume interventional centre with strong academic links.
You can find full details and apply here:
apply.jobs.scot.nhs.uk/Job/J…
Please share
Paul Rocchiccioli retweeted
Thank you to this patient for their kind words about the fantastic care they received from #TeamJubilee.
If you would like to share your experience with us, leave a comment below or contact CommsEnquiries@gjnh.scot.nhs.uk
Paul Rocchiccioli retweeted
A #JACC State-of-the-Art Review outlines a multidisciplinary, longitudinal approach to cardiogenic shock care aimed at "providing a clinically actionable structure for care pathways, resource planning and future research."
Read more: 🔗 bit.ly/4mjILIA #CardioX
Paul Rocchiccioli retweeted
All the best to #TeamJubilee’s Ross McVean, who is preparing to take on the London Marathon
Ross, a Cardiac Physiologist at NHS Golden Jubilee, is running the iconic 26.2 miles to raise money for a cause close to his heart @Cardiomyopathy
Read more:
nhsgoldenjubilee.co.uk/news/…
Paul Rocchiccioli retweeted
New EAPC/ESC/ACC Statement updates abnormal CV findings in Masters athletes. Expert guidance on AF, bradyarrhythmias, ventricular arrhythmias, CAD, aortic dilatation, myocardial fibrosis, & exercise-induced arrhythmogenic cardiomyopathy jacc.org/doi/10.1016/j.jacc.… #JACC #SportsCardio
Paul Rocchiccioli retweeted
Delighted to see our fellow Daniel present the results of TARTAN-HF (Targeted assessment in high-risk patients with diabetes to identify undiagnosed heart failure) as a late-breaking featured science presentation today at #ACC2026
clinicaltrials.gov/study/NCT…
Paul Rocchiccioli retweeted
HOST-EXAM trial 10-year results: Clopidogrel monotherapy is superior to aspirin for chronic maintenance after PCI, significantly reducing both thrombotic and bleeding events. #ACC26 View slides here: clinicaltrialresults.org/wp-…
Paul Rocchiccioli retweeted
#CHIP-BCIS3
Patients: Stable patients, No Anterior STEMI, No Cardiogenic Shock
🚫 Primary endpoint negative — win ratio 0.85 (no benefit signal)
⚠️ Mortality concern — higher CV death with Impella (HR 1.91)
➖ No consistent efficacy — MI, stroke, hospitalization largely neutral
🩸 Safety penalty — more bleeding & vascular complications
🧠 Take-home — Standard of Care remains the standard, Impella- no clinical benefit + possible harm → rethink routine use of elective Unloading with "protected" PCI
#ACC26
@mmamas1973 @mirvatalasnag @hollymorgs
Paul Rocchiccioli retweeted
Easy to say in hindsight, of course, but putting a micro-axial flow pump 30 minutes before PCI in STEMIs without shock always struck me as more risky than beneficial—mostly for the delay it adds. And it quintuples BARC 3 bleeding. For the umpteenth time in a STEMI trial: nothing beats reopening the vessel, quickly. #ACC26
jacc.org/doi/10.1016/j.jacc.…
Paul Rocchiccioli retweeted
Now we know why Rishi Sunak refuses to negotiate with NHS staff.
He wants the strikes to go ahead, so he can blame doctors and nurses for his failure.
#PMQs
Paul Rocchiccioli retweeted
🧵1/
🫀 Big left atrium: athlete’s heart or early disease?
In our new EHJ Cardiovascular Imaging paper, we introduce the LA:LV ratio to distinguish adaptive vs. maladaptive remodeling.
~0.5 = physiological
≥0.75 = suspect pathology
👉 doi.org/10.1093/ehjci/jeaf33…
#SportsCardiology
Paul Rocchiccioli retweeted
Congratulations to my son Chris on his first academic publication - in a high quality journal!
And this was from his MSc student project.
PhD nearly completed ...
doi.org/10.1038/s41598-025-2…
Paul Rocchiccioli retweeted
Yesterday, #TeamJubilee’s Lynsay Boyle and Hayley Doak were raising awareness for #WorldDiabetesDay, letting staff and visitors know about the symptoms and risks of diabetes, and steps to take to lower the risk of type 2 diabetes.
More info: diabetes.org.uk
Paul Rocchiccioli retweeted
Beta-Blocker Trialists’ Collaboration
Meta analysis of 5 RCTS of those with MI & LVEF >/= 50% shows beta blockers do not decrease death, MI or HF at 3.6 years
So is it still a GDMT of AMI when EF>/=50%?
#AHA25 #CVprev @NEJM
Presented at #AHA25:
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
@AHAScience
ALT Kaplan–Meier curves of the cumulative incidence of death from any cause, myocardial infarction, or heart failure (the composite primary end point).
Paul Rocchiccioli retweeted
#VESALIUS-CV is the first large-scale randomized trial of a PCSK9 inhibitor (evolocumab) in primary prevention, showing that aggressive LDL-C lowering reduces first major cardiovascular events in patients without prior MI or stroke.
This confirms that atherosclerotic risk begins well before the 1st event & can be safely modified.
Congratulations to these investigators for this important study #AHA25 #LBCT #CVPrev #CardioTwitter
#VESALIUSCV trial #LBCT #AHA25 #VESALIUS
🫀RCT: role of PCSK9i in those without ASCVD (primary prevention in those at high risk) with LDL>90 on background of lipid lowering tx; followed for 4.5 y
🫀43% women 👏🏽👏🏽
🫀mean LDL 121 with LDL⤵️ with tx to 45
💥19% relative risk reduction with tx vs placebo of MACE including all cause mortality by itself
